Arizona College of Osteopathic Medicine, Glendale, AZ, USA.
Lake Erie College of Osteopathic Medicine, Bradenton, FL, USA.
J Dermatolog Treat. 2022 May;33(3):1606-1607. doi: 10.1080/09546634.2020.1870648. Epub 2021 Jan 12.
The occurrence of the COVID-19 pandemic has raised new uncertainties for dermatologists and their patients, importantly concerning initiation and continuation of immunosuppressants for dermatological conditions at this time. We review two phase III trials of rituximab, a chimeric CD20 monoclonal antibody, used for the treatment of pemphigus vulgaris. Without specific data studying rituximab use and susceptibility of SARS-CoV-2, we hope to utilize available data in order to assist clinician decision making for rituximab in the context of the pandemic.
COVID-19 大流行的出现给皮肤科医生及其患者带来了新的不确定性，重要的是，此时要考虑开始和继续使用免疫抑制剂治疗皮肤病。我们回顾了两项关于利妥昔单抗（一种嵌合 CD20 单克隆抗体）治疗寻常型天疱疮的 III 期临床试验。由于没有专门研究利妥昔单抗使用和 SARS-CoV-2 易感性的数据，我们希望利用现有数据，以便在大流行背景下为利妥昔单抗的使用提供临床医生决策的依据。
